ArticlePDF Available

Associations between classic psychedelics and nicotine dependence in a nationally representative sample



Tobacco use is the single largest cause of preventable death worldwide, but none of the established treatments aimed at smoking cessation work for a majority of smokers. As such, there is an urgent need for interventions capable of reliably treating nicotine addiction. The use of classic psychedelics has been associated with lower odds of many forms of substance dependence. Here we tested whether lifetime use of classic psychedelics (tryptamine, lysergamide, and phenethylamine) is associated with lower odds of current nicotine dependence. We tested these associations in a sample of 214,505 adult participants in the National Survey on Drug Use and Health (2015–2019) using multivariable logistic regression models. Lifetime psilocybin use was associated with reduced odds of odds of current nicotine dependence (aOR 0.87–0.93). Lifetime use of peyote and mescaline also conferred reduced odds of multiple subdomains of a main nicotine dependence measure (Nicotine Dependence Syndrome Scale [NDSS]) (aOR 0.79–0.91). Conversely, lifetime use of LSD was associated with increased odds of nicotine dependence (aOR 1.17–1.24). Psilocybin, mescaline, and peyote use are associated with lowered odds of nicotine dependence. Experimental studies are needed to establish whether these associations are causal. These results make the case for further research into the efficacy of both tryptamine and phenethylamine psychedelics in promoting smoking cessation.
Scientic Reports | (2022) 12:10578 |
Associations between classic
psychedelics and nicotine
dependence in a nationally
representative sample
Grant Jones1*, Joshua Lipson2 & Matthew K. Nock1
Tobacco use is the single largest cause of preventable death worldwide, but none of the established
treatments aimed at smoking cessation work for a majority of smokers. As such, there is an urgent
need for interventions capable of reliably treating nicotine addiction. The use of classic psychedelics
has been associated with lower odds of many forms of substance dependence. Here we tested
whether lifetime use of classic psychedelics (tryptamine, lysergamide, and phenethylamine) is
associated with lower odds of current nicotine dependence. We tested these associations in a sample
of 214,505 adult participants in the National Survey on Drug Use and Health (2015–2019) using
multivariable logistic regression models. Lifetime psilocybin use was associated with reduced odds
of odds of current nicotine dependence (aOR 0.87–0.93). Lifetime use of peyote and mescaline also
conferred reduced odds of multiple subdomains of a main nicotine dependence measure (Nicotine
Dependence Syndrome Scale [NDSS]) (aOR 0.79–0.91). Conversely, lifetime use of LSD was associated
with increased odds of nicotine dependence (aOR 1.17–1.24). Psilocybin, mescaline, and peyote
use are associated with lowered odds of nicotine dependence. Experimental studies are needed to
establish whether these associations are causal. These results make the case for further research into
the ecacy of both tryptamine and phenethylamine psychedelics in promoting smoking cessation.
Tobacco is the single largest cause of preventable death worldwide, killing 8.7 million people each year, a number
that continues to increase, despite the steady expansion of prevention measures across the globe1. In addition,
tens of millions of individuals suer from a range of avoidable respiratory, cardiovascular, and other illnesses as
a result of smoking tobacco, and over the past two years, studies have demonstrated that cigarette smokers are
more likely to be hospitalized or die from COVID-191. In the United States, 70% of current adult smokers say
that they want to quit, and in 2018, 55% reported attempting to quit at least once in the past year2,3. However, to
date, even the most eective pharmacological and behavioral smoking cessation treatments fail to promote long-
term abstinence in a large majority of people who use them4,5. e development of more eective, reliable, and
long-lasting smoking cessation treatments represents one of the most important health needs around the world1.
In recent years, researchers have begun to explore the use of classic psychedelics (Greek for “mind-manifest-
ing”), typically in the context of a psychotherapeutic framework, as a treatment for a host of dierent forms of
addiction and substance abuse, including addiction to smoking tobacco. Classic psychedelics are found in nature
or can be synthesized from natural compounds, and have been demonstrated to elicit mystical-type experiences
characterized by self-transcendent awe that can have lasting personal and spiritual signicance69. On a pharma-
cological level, they are dened by their agonist activity at the 5-HT2A receptor site10. Six of the main substances
included in this class are: the tryptamine psilocybin (the active component within “magic mushrooms”), the
phenethylamines peyote (a psychoactive cactus) and mescaline (the active compound within peyote), ayahuasca
(a psychoactive brew including Banisteriopsis caapi and Psychotria viridis), DMT (the active component within
ayahuasca), and lysergic acid diethylamide (LSD; synthesized from the ergot fungus).
Recent evidence has linked classic psychedelics to lowered odds of substance abuse and dependence. In a
sample of 44,678 respondents who reported lifetime use of illicit opioids in the National Survey on Drug Use
and Health (NSDUH), Pisano etal. (2017)found that psychedelic use was associated with 27% reduced risk
of past-year opioid dependence, and 40% reduced risk of past-year opioid abuse11. Smaller-scale attempts at
measuring the association between naturalistic use of classic psychedelics, on one hand, and misuse of other
1Department of Psychology, Harvard University, 33 Kirkland St, Cambridge, MA 02138, USA. 2Teacher’s College,
Columbia University, New York, USA. *email:
Content courtesy of Springer Nature, terms of use apply. Rights reserved
Scientic Reports | (2022) 12:10578 |
addictive substances, including alcohol, cannabis, and stimulants, on the other, have yielded results suggesting
an association between psychedelic use and large-scale remission from abuse disorders12,13. In addition, recent
evidence has emerged to suggest that the naturalistic use of mescaline, specically, is associated with reductions
in the symptoms of alcohol and drug use disorders14.
Additionally, over the past decade, a line of research by Johnson and colleagues has suggested an association
between the use of classic psychedelics and smoking cessation in both experimental and naturalistic settings.
First, in an open-label pilot study that combined two or three doses of psilocybin with a program of cognitive
behavioral therapy (CBT) targeted at smoking cessation, Johnson etal. (2014)found that 12 of 15 (80%) partici-
pants met the criteria for smoking abstinence at 6-month follow-up15. In a follow-up study on psilocybin-assisted
smoking cessation therapy, Johnson etal. (2017a)identied a 67% rate of smoking abstinence at 12-month
follow-up, compared to a 31% rate of abstinence at 12months post-treatment for gold standard smoking cessa-
tion medications16. However, these researchers note their ndings are limited by the small size and homogeneity
of their sample.
Johnson etal.(2017b)complemented these experimental clinical data by examining the eects of psychedelics
on smoking behavior in a naturalistic context17. e authors recruited 358 individuals who reported having quit
or reduced smoking aer ingesting any psychedelic in a non-laboratory setting a year or more ago, and found
that at the time of survey, 38% of participants reported continuous smoking cessation, and an additional 28%
reported persistent reduction from pre-psychedelic smoking levels.
Despite the novel contribution Johnson etal. (2017b)makes to the literature, there are signicant limitations
to this study as well. e authors acknowledge the issue of selection bias, given that the survey was distributed
to websites visited by individuals interested in psychedelics (e.g., www. erowid. org, www. shroo mery. org). Addi-
tionally, the sample was considerably male-skewed, with only 15% of respondents identifying as female. eir
sample also was heavily skewed toward users of LSD and psilocybin, with only a small minority reporting use
of phenethylamine psychedelics.
e current study seeks to address the limitations of past studies by testing the associations between lifetime
use of classic psychedelics and current (past month) nicotine dependence using a large-scale nationally-repre-
sentative sample. Although such an approach cannot be used to infer a causal association between psychedelic
use and nicotine dependence, the large and representative nature of this sample allows us to glean critical insights
about the robustness of the associations between psychedelic use and nicotine dependence and to build on the
existing small-scale research on this matter.
Sample. Data are from the National Survey on Drug Use and Health (NSDUH; 2015–2019) (unweighted
N = 214,505), a survey that assesses behavior, health, and substance use outcomes in U.S citizens ages 12years
and older. Currently incarcerated individuals, individuals experiencing homelessness, and active-duty military
service members are not included in the NSDUH. Given that data for this project are publicly available, this
study was determined to be exempt from review by the Harvard IRB. All study procedures were carried out in
accordance with the relevant guidelines and regulations.
Measures. Dependent variables. Our main dependent variables were two measures assessing past month
nicotine dependence within the NSDUH: composite scores on the Nicotine Dependence Syndrome Scale
(NDSS) and the Fagerstrom Test of Nicotine Dependence (FTND), recently renamed and known elsewhere as
the Fagerstrom Test of Cigarette Dependence (FTCD). e NSDUH NDSS composite measure is based on 17
questions that assess various aspects of nicotine dependence. Scores on each question ranged from 1 (not at all
true) to 5 (extremely true) (some items were reverse coded). e NDSS composite score represents the mean
of these 17 questions. Individuals were coded as past–month nicotine–dependent based on the NDSS if they
received a score of 2.75 or above on the composite NDSS measure. e NSDUH FTND measure, by contrast, is
based on a single criterion: whether one smokes within 30min of waking up. Individuals meeting this criterion
were coded as dependent based on the FTND.
In addition to estimating models based on these two composite scores, we also estimated models based on
subdomains of the NDSS. e NSDUH indicates that the 17 questions comprising the NDSS can be grouped
into ve subdomains: smoking drive (compulsion to smoke), nicotine tolerance, continuous smoking, behavioral
priority (prioritizing smoking over other reinforcing activities), and stereotypy (having xed smoking patterns).
us, we took the mean for all questions within each subdomain and rounded these values to the nearest integer
to create ordinal subdomain variables ranging from 1 (low dependence) to 5 (high dependence).
Independent variables/covariates. Our main independent variables were NSDUH items assessing lifetime use
(yes/no) of the following classic psychedelics: psilocybin, peyote, mescaline, and LSD. Additionally, to test the
specicity of any observed associations, we included as independent variables items assessing lifetime use of
various legal/medicinal and illegal substances: MDMA/ecstasy, heroin, PCP, inhalants, cocaine, pain relievers,
tranquilizers, stimulants, sedatives, and marijuana. Several sociodemographic variables were included as a priori
covariates: sex, age, race/ethnicity, marital status, income, educational attainment, and self-reported engagement
in risky behavior.
Analysis plan. We used multivariable logistic regression to assess the associations between each independ-
ent variable and the two main nicotine dependence measures (the NDSS and FTND composite variables). For
our rst and second models, we simultaneously entered all of our predictor variables, with the aim of gauging
their respective associations with the NDSS and the FTND composites, respectively.
Content courtesy of Springer Nature, terms of use apply. Rights reserved
Scientic Reports | (2022) 12:10578 |
Additionally, given that our subdomain variables are scored ordinally, we ran ve ordinal logistic regression
models to test the associations between our predictor variables and each of the ve nicotine dependence sub-
domains of the NDSS. For each of these models, we simultaneously entered all of our predictor variables, and
examined their association with the given NDSS subdomain.
We used the ‘Survey’ package in R to incorporate the complex survey design and sampling weights of the
NSDUH into our models18. Additionally, we used the ‘lmtest’ package to conduct our signicance tests for the
ordinal logistic regression models in this study19, as the ‘Survey’ package does not generate p-values for this
class of models.
Demographic dierences between those who do versus do not meet criteria for past-month nicotine dependence
are presented in Table1. Individuals with nicotine dependence were more likely to be divorced or never married,
less formally educated, younger, Non-Hispanic White, lower-income, and to report slightly more engagement
in risky-behavior.
Results from the logistic regression models testing the associations between lifetime use of all substances and
the NDSS and FTND composite measures are presented in Table2. As hypothesized, lifetime psilocybin use was
associated with lower odds of current (past month) nicotine dependence as measured by both the NDSS (aOR
0.90) and FTND (aOR 0.87). No other substances examined were associated with lower odds of these measures.
Several, including LSD, were associated with increased odds of nicotine dependence.
Results from the models testing the associations between lifetime substance use and the ve subdomains of the
NDSS are presented in Table3. Mescaline use was associated with lower odds of all ve subdomains of nicotine
dependence (aOR 0.79–0.86) and peyote use was associated with lowered odds of the nicotine tolerance (aOR
0.89) and continuous smoking (aOR 0.88) subdomains. Psilocybin use was associated with lower odds of the
behavioral priority subdomain (aOR 0.93). Aside from one instance of sedatives conferring decreased odds of the
stereotypy subdomain (aOR 0.93), all other substances were either not associated with nicotine dependence or
associated with increased odds of nicotine dependence. Additionally, each of the aforementioned demographic
covariates shared signicant, varying relationships to nicotine dependence across all of our models.
e primary nding from this study is that the lifetime use of classic psychedelics (both tryptamine and pheneth-
ylamine) was associated with lower odds of current nicotine dependence as well as the sub-domains underlying
this construct. Psilocybin conferred lowered odds of both composite measures of past month nicotine depend-
ence in the NSDUH (the NDSS and the FTND), and peyote and mescaline conferred lowered odds of various
subdomains of the NDSS. Aside from a singular instance of sedatives conferring lowered odds of one nicotine
dependence subdomain, all other substances either shared no association with nicotine dependence or conferred
increased odds of nicotine dependent behavior.
Although these results cannot be used to infer a causal association, they document the robust association
between the lifetime use of psilocybin, peyote, and mescaline and the lowered odds of nicotine dependence.
Moreover, these results suggest the possibility that psychedelic use might also be protective against future nico-
tine dependence, beyond the single time point captured in the dataset we analyzed. ese results are timely, as
the National Institute of Health (NIH) recently funded a multi-site clinical trial testing psilocybin for treating
nicotine dependence20. at trial marks the rst time in 50years that the NIH is funding a trial involving psych-
edelics. is study further supports the need for trials that test the therapeutic ecacy of psilocybin, peyote, and
mescaline for treating nicotine dependence and potentially other substance use disorders as well.
ese ndings also are consistent with other population-based survey research on classic psychedelics sug-
gesting that naturalistic use of LSD in particular is associated with increased odds of adverse outcomes21,22, despite
evidence for LSD’s therapeutic ecacy under clinical administration23. Negative outcomes have been associated
with the use of some psychedelics, such as paranoia, stress, anxiety, and increased odds of psychosis24, and might
underlie the association between LSD use and increased odds of nicotine dependence. Additionally, it is possible
that LSD use in particular is confounded with other factors associated with nicotine dependence. Alternatively,
naturalistic use of LSD might be associated with dierent cultural framing and settings than naturalistic use of
psilocybin, accounting for a higher probability of adverse outcomes. Further investigation into the potentially
adverse eects of classic psychedelics, and the potential harm of LSD use in naturalistic contexts, is warranted.
Limitations. ese results should be interpreted in the context of several major limitations. First, these
results are based on cross-sectional data and cannot be used to draw causal inferences about the observed asso-
ciations. ird-variable factors and pre-existing dierences between those who have versus have not used psilo-
cybin, peyote, and mescaline very possibly contribute to the associations we observed. Longitudinal studies and
clinical trials are needed to better understand the temporal and causal associations between psilocybin, peyote,
and mescaline use and lowered odds of nicotine dependence. Additional investigations into potential third vari-
able factors can have the additional benet of identifying factors that may be protective against nicotine depend-
ence as well.
Second, the questions in the NSDUH are based on self-report, and thus, for substance use and nicotine
dependence questions, under-reporting may be a complicating factor in our analyses and conclusions. Future
studies that strictly monitor and observe substance use can address this limitation.
ird, this study cannot clearly establish that classic psychedelic use took place prior to the onset of nicotine
dependence, given the overlapping time horizons of these two measures. However, classic psychedelic use was
Content courtesy of Springer Nature, terms of use apply. Rights reserved
Scientic Reports | (2022) 12:10578 |
assessed over an entire lifetime and nicotine dependence was assessed over the past month; hence, many indi-
viduals likely engaged in use of classic psychedelics prior to the onset of nicotine dependence.
Fourth, we cannot establish recency or frequency of classic psychedelic use in our study, given the binary
nature of our lifetime use variable. Nevertheless, causal interpretations of our ndings remain plausible despite
this limitation, as psilocybin has been shown to elicit lasting reductions in nicotine dependence aer just two
to three administrations16.
Fih, multicollinearity represents a possible limitation to our ndings. Multicollinearity refers to substantial
levels of correlation between independent variables; furthermore, multicollinearity increases the standard errors
within a given model and can thus result in unstable model estimates. Multicollinearity is primarily measured
Table 1. Demographic characteristics of those with and without nicotine dependence (ND). ND Nicotine
Dependence. 1 Chi-squared test with Rao & Scott’s second-order correction.
Characteristic Does not have ND (weighted %)
(N = 188,367) (%) Has ND (weighted %) (N = 26,138) (%) p-value1
Marital status < 0.001
Married 54 36
Widowed 6.0 5.5
Divorced or separated 13 24
Never been married 28 35
Education < 0.001
5th grade or lower 1.3 0.5
6th grade 1.2 0.4
7th grade 0.4 0.7
8th grade 1.0 1.9
9th grade 1.5 3.6
10th grade 1.7 5.0
11th or 12th grade 4.5 9.0
High school diploma/GED 23 37
Some college credit 21 24
As soci ate’s 9.4 8.2
Bachelor’s or higher 34 9.9
Age < 0.001
18–25 14 12
26–34 16 19
35–49 24 29
50+ 46 40
Sex < 0.001
Male 48 53
Female 52 47
Race < 0.001
Non-Hispanic White 63 74
Non-Hispanic Black 12 13
Non-Hispanic Native American/Alaska
Native 0.5 0.9
Non-Hispanic Native Hawaiian/Pacic
Islander 0.4 0.4
Non-Hispanic Asian 6.1 1.7
Non-Hispanic more than one race 1.6 2.7
Hispanic 17 8.0
Yearly household income < 0.001
< $20,000 15 29
$20,000–$49,999 29 36
$50,000–$74,999 16 14
$75,000 + 40 21
Self-reported engagement in risky behavior < 0.001
Never 56 48
Seldom 32 33
Sometimes 11 16
Always 1.2 2.8
Content courtesy of Springer Nature, terms of use apply. Rights reserved
Scientic Reports | (2022) 12:10578 |
by Variance Ination Factors (VIFs) and a VIF above 10 indicates the presence of multicollinearity for a given
independent variable. We report the VIFs for the independent variables within our study in Supplemental Table1.
As indicated within this table, some of our independent variables have VIFs above 10, indicating that multicol-
linearity is present within our study. However, the impact of multicollinearity on our results is likely limited,
as our large sample size serves to minimize the impact that inated standard errors may otherwise have on the
integrity of our models25. Nevertheless, future studies can further address this limitation by using modeling
approaches such as ridge regression that are designed to handle multicollinearity.
Lastly, our approach to calculating p-values in this study features limitations as well. As previously indicated,
we used the ‘lmtest’ package to conduct Wald tests (quasi-t tests) and generate p-values for our ordinal regression
models19. However, one can plausibly conduct z-tests for the ordinal regression models within this study as well.
Table 2. Associations between lifetime substance use and two measures of nicotine dependence. Signicant
values conferring lowered odds of nicotine dependenceare in bold. 1 *p < 0.05; **p < 0.01; ***p < 0.001; aOR
adjusted odds ratio, CI condence interval.
Lifetime use
Nicotine dependence (NDSS) Nicotine dependence (FTND)
aOR (95% CI)1p-value aOR (95% CI) p-value
Psilocybin 0.90* (0.83, 0.98) 0.017 0.87* (0.78, 0.97) 0.021
Peyote 0.92 (0.77, 1.10) 0.310 0.99 (0.85, 1.16) 0.941
Mescaline 0.90 (0.75, 1.06) 0.178 0.88 (0.76, 1.02) 0.075
LSD 1.22*** (1.13, 1.32) 2.37e−04 1.17** (1.07, 1.28) 0.004
MDMA/ecstasy 1.13* (1.03, 1.24) 0.018 1.13* (1.03, 1.25) 0.017
PCP 1.17* (1.02, 1.34) 0.026 1.06 (0.93, 1.21) 0.316
Cocaine 1.56*** (1.47, 1.67) 6.41e−08 1.64*** (1.51, 1.78) 1.97e−07
Heroin 1.83*** (1.62, 2.07) 1.48e−06 1.89*** (1.69, 2.11) 4.20e−07
Inhalants 1.08 (0.99, 1.17) 0.064 1.00 (0.91, 1.10) 0.971
Pain relievers 1.28*** (1.19, 1.37) 2.74e−05 1.13*** (1.07, 1.19) 9.61e−04
Tranquilizers 1.20*** (1.13, 1.27) 6.83e−05 1.18*** (1.11, 1.26) 2.07e−04
Stimulants 0.99 (0.93, 1.06) 0.799 0.95 (0.88, 1.02) 0.148
Sedatives 1.10* (1.02, 1.19) 0.015 1.03 (0.95, 1.11) 0.397
Marijuana 3.03*** (2.80, 3.28) 1.44e−10 2.71*** (2.53, 2.90) 1.00e−10
Table 3. Associations between lifetime substance use and the ve NDSS subdomains. Signicant values
conferring lowered odds of nicotine dependenceare in bold. 1 *p < 0.05; **p < 0.01; ***p < 0.001, aOR adjusted
odds ratio, CI condence interval.
Lifetime use
Smoking drive Nicotine tolerance Continuous smoking Behavioral priority Stereotypy
aOR (95% CI)1p-value aOR (95% CI) p-value aOR (95% CI) p-value aOR (95% CI) p-value aOR (95% CI) p-value
Psilocybin 0.96 (0.90, 1.01) 0.170 0.96 (0.91, 1.02) 0.188 0.98 (0.92, 1.04) 0.475 0.93* (0.88, 0.99) 0.048 0.97 (0.91, 1.03) 0.335
Peyote 0.90 (0.81, 0.99) 0.061 0.89* (0.81, 0.98) 0.038 0.88* (0.80, 0.96) 0.022 0.91 (0.83, 1.00) 0.081 0.90 (0.82, 0.99) 0.058
Mescaline 0.82** (0.73,
0.92) 0.008 0.79** (0.72,
0.88) 0.002 0.84* (0.75, 0.93) 0.010 0.83** (0.74,
0.92) 0.008 0.86* (0.77, 0.95) 0.015
LSD 1.24*** (1.17,
1.32) 4.54e−05 1.21*** (1.14,
1.28) 1.61e−04 1.22*** (1.15,
1.29) 8.64e−05 1.21*** (1.14,
1.28) 1.09e−04 1.17*** (1.11,
1.24) 3.55e−04
MDMA/ecstasy 1.25*** (1.19,
1.32) 1.49e−05 1.32*** (1.25,
1.38) 1.57e−06 1.26*** (1.19,
1.33) 1.59e−05 1.23*** (1.17,
1.30) 1.90e−05 1.26*** (1.20,
1.31) 4.01e−06
PCP 1.01 (0.92, 1.12) 0.795 1.00 (0.91, 1.10) 0.954 1.01 (0.92, 1.11) 0.851 1.03 (0.94, 1.13) 0.521 1.03 (0.93, 1.13) 0.597
Cocaine 1.70*** (1.62,
1.79) 5.24e−09 1.68*** (1.60,
1.76) 3.50e−09 1.66*** (1.58,
1.74) 7.14e−09 1.67*** (1.60,
1.75) 3.61e−09 1.60*** (1.53,
1.68) 9.75e−09
Heroin 1.73*** (1.56,
1.93) 3.22e−06 1.70*** (1.54,
1.88) 2.72e−06 1.57*** (1.42,
1.73) 9.72e−06 1.51*** (1.36,
1.67) 2.38e−05 1.31*** (1.19,
1.44) 3.81e−04
Inhalants 1.03 (0.98, 1.10) 0.285 1.02 (0.96, 1.07) 0.599 1.00 (0.94, 1.06) 0.960 1.01 (0.96, 1.07) 0.643 0.96 (0.90, 1.02) 0.190
Pain Relievers 1.12*** (1.07,
1.16) 4.69e−04 1.11*** (1.07,
1.16) 7.16e−04 1.10** (1.06, 1.15) 0.002 1.09** (1.05, 1.14) 0.003 1.06* (1.02, 1.10) 0.024
Tranquilizers 1.17*** (1.12,
1.22) 5.98e−05 1.17*** (1.12,
1.21) 4.09e−05 1.14*** (1.09,
1.19) 2.58e−04 1.15*** (1.10,
1.21) 1.47e−04 1.10** (1.05, 1.15) 0.003
Stimulants 1.10*** (1.06,
1.14) 8.40e−04 1.11*** (1.07,
1.16) 5.11e−04 1.09** (1.05, 1.13) 0.002 1.10** (1.06, 1.14) 0.001 1.09** (1.05, 1.13) 0.002
Sedatives 1.00 (0.95, 1.05) 0.966 0.98 (0.94, 1.03) 0.427 0.98 (0.93, 1.02) 0.337 0.96 (0.92, 1.01) 0.163 0.93* (0.89, 0.97) 0.013
Marijuana 2.80*** (2.69,
2.91) 2.66e−12 2.80*** (2.69,
2.92) 2.45e−12 2.79*** (2.68,
2.90) 1.93e−12 2.78*** (2.66,
2.90) 3.53e−12 2.68*** (2.57,
2.79) 4.39e−12
Content courtesy of Springer Nature, terms of use apply. Rights reserved
Scientic Reports | (2022) 12:10578 |
Z-tests are typically used when one is certain that their data are normally distributed, but can also be used for a
sample with an unknown distribution if the sample size is large, as is the case with our study26. For transparency,
we also report the p-values yielded from z-tests for our ordinal regression models in Supplemental Table2. As
one can see from this table, our pattern of results remain largely unchanged, regardless of the approach one takes
for signicance testing within this study.
Potential mechanisms. Several distinct pharmacological and psychological mechanisms may underlie
our observed ndings, if the associations reported above are indeed causal. e eects of psilocybin, peyote, and
mescaline on the serotonin system may mediate the link between these substances and lowered odds of nicotine
dependence. It is currently understood that these substances primarily act as serotonin (5-HT2A) receptor ago-
nists, binding to a site typically targeted by serotonin. It has been suggested that downstream changes in func-
tional connectivity, information processing, and neuroplasticity lead to psychedelic states of consciousness with
therapeutic potential2729. Aberrant serotonin neurotransmission is implicated in many elements of addiction,
including attentional and motivational biases and impulse control decits associated with compulsive substance
use3033. Accordingly, serotonergic pharmacological interventions have been proposed as a promising treatment
option for nicotine dependence as well34,35. Future research that deepens our knowledge of the serotonergic
eects of classic psychedelics may shed light on their potential role in treating nicotine addiction.
In addition, the spiritual experiences elicited by classic psychedelics, best characterized as experiences of
self-transcendent awe, represent a plausible core psychological mechanism mediating our associations. In the
open label trial of psilocybin for nicotine dependence conducted by Johnson etal.(2014), reductions in nicotine
dependence were signicantly correlated with measures of mystical experience on psilocybin session days, as well
as with retrospective ratings of the personal meaning and spiritual signicance of the psilocybin experience36.
Spirituality is oen linked with positive substance abuse recovery outcomes, more broadly3739. Additional inquir-
ies into the role of self-transcendent spiritual experiences in the alleviation of addiction can shed light on the
potential link between classic psychedelics and lowered odds of nicotine dependence.
ere are several other potential psychological mechanisms that may underlie our observed relationships as
well, many of which have been described by Bogenschutz and Pommy30. Classic psychedelics can cause lasting
improvements in mood and well-being6 that in turn may reduce the risk for addiction and relapse40,41. Psych-
edelics also may cause shis in personality traits that lead to downstream reductions in nicotine dependence as
well4244. e aforementioned changes elicited by psychedelic experiences (e.g. increases in mood and spirituality,
changes in personality) may also elicit increases in self-ecacy and motivation that further support reductions
in addictive behavior30,45. Importantly, these proposed mechanisms are preliminary, and additional research is
needed to help determine which factors mediate the link between use of classic psychedelics and lowered odds
of nicotine dependence.
is study provides preliminary evidence supporting the association between use of classic psychedelics of both
the tryptamine and phenethylamine classes, and lowered odds of nicotine dependence. Future clinical trials are
needed to test whether this link is causal. Additional inquiry may also identify mediators and third-variable
factors underlying our ndings, which may act as protective factors against nicotine dependence. is study
represents an important step toward understanding the link between use of classic psychedelics and smoking
behavior in a naturalistic, large-sample context, as well as incremental progress towards reducing rates of nicotine
addiction and stemming a signicant source of morbidity and mortality worldwide.
Data availability
e data supporting the ndings from this project are publicly available at the Substance Abuse & Mental Health
Data Archive (SAMHDA) at the following web address: https:// www. data les. samhsa. gov/.
Received: 14 November 2021; Accepted: 13 June 2022
1. World Health Organization. WHO Report on the Global Tobacco Epidemic 2021: Addressing New and Emerging Products (World
Health Organization, 2021).
2. Babb, S. Quitting smoking among adults: United States, 2000–2015. MMWR Morb. Mortal Wkly. Rep. https:// doi. org/ 10. 15585/
mmwr. mm655 2a1 (2017).
3. Creamer, M. R. et al. Tobacco product use and cessation indicators among adults: United States, 2018. MMWR Morb. Mortal Wkly.
Rep. 68, 1013–1019 (2019).
4. Cahill, K., Stevens, S. & Lancaster, T. Pharmacological treatments for smoking cessation. JAMA 311, 193–194 (2014).
5. Mottillo, S. et al. Behavioural interventions for smoking cessation: A meta-analysis of randomized controlled trials. Eur. Heart J.
30, 718–730 (2009).
6. Griths, R. R., Richards, W. A., McCann, U. & Jesse, R. Psilocybin can occasion mystical-type experiences having substantial and
sustained personal meaning and spiritual signicance. Psychopharmacology 187, 268–283 (2006).
7. Nour, M. M., Evans, L. & Carhart-Harris, R. Psychedelics, Personality and Political Perspectives. J Psychoactive Drugs 49, 182–191
8. Yaden, D. B., Haidt, J., Ho od, R. W. Jr., Vago, D. R. & Newberg, A. B. e varieties of self-transcendent experience. Rev. Gen. Psychol.
21, 143–160 (2017).
9. Hendricks, P. S. Awe: A putative mechanism underlying the eects of classic psychedelic-assisted psychotherapy. Int. Rev. Psychiatry
30, 331–342 (2018).
10. Johnson, M. W., Hendricks, P. S., Barrett, F. S. & Griths, R. R. Classic psychedelics: An integrative review of epidemiology,
therapeutics, mystical experience, and brain network function. Phamacol. er. 197, 83–102 (2019).
Content courtesy of Springer Nature, terms of use apply. Rights reserved
Scientic Reports | (2022) 12:10578 |
11. Pisano, V. D. et al. e association of psychedelic use and opioid use disorders among illicit users in the United States. J. Psychop-
harmacol. 31, 606–613 (2017).
12. Garcia-Romeu, A. et al. Persisting reductions in cannabis, opioid, and stimulant misuse aer naturalistic psychedelic use: An
online survey. Front. Psychiatry 10, 955 (2019).
13. Garcia-Romeu, A. et al. Cessation and reduction in alcohol consumption and misuse aer psychedelic use. J. Psychopharmacol.
33, 1088–1101 (2019).
14. Agin-Liebes, G. et al. Naturalistic use of mescaline is associated with self-reported psychiatric improvements and enduring positive
life changes. ACS Pharmacol. Transl. Sci. 4, 543–552 (2021).
15. Johnson, M. W., Garcia-Romeu, A., Cosimano, M. P. & Griths, R. R. Pilot study of the 5-HT2AR agonist psilocybin in the treat-
ment of tobacco addiction. J. Psychopharmacol. 28, 983–992 (2014).
16. Johnson, M. W., Garcia-Romeu, A. & Griths, R. R. Long-term follow-up of psilocybin-facilitated smoking cessation. Am. J. Drug.
Alcohol Abuse 43, 55–60 (2017a).
17. Johnson, M. W., Garcia-Romeu, A., Johnson, P. S. & Griths, R. R. An online survey of tobacco smoking cessation associated with
naturalistic psychedelic use. J. Psychopharmacol. 31, 841–850 (2017b).
18. Lumley, T. Survey: Analysis of complex survey samples (Springer, 2020).
19. Hothorn, T. et al. lmtest: Testing Linear Regression Models (Springer, 2022).
20. Johns Hopkins Medicine Newsroom. Johns Hopkins Medicine Receives rst federal grant for psychedelic treatment research in
50 years. in Johns Hopkins Medicine Newsroom. (2021). https:// www. hopki nsmed icine. org/ news/ newsr oom/ news- relea ses/ johns-
hopki ns- medic ine- recei ves- rst- feder al- grant- for- psych edelic- treat ment- resea rch- in- 50- years. Accessed 9 Nov 2021.
21. Jones, G. M. & Nock, M. K. Exploring protective associations between the use of classic psychedelics and cocaine use disorder : A
population-based survey study. Sci. Rep. 12, 2574 (2022).
22. Jones, G. M. & Nock, M. K. MDMA/ecstasy use and psilocybin use are associated with lowered odds of psychological distress and
suicidal thoughts in a sample of US adults. J. Psychopharmacol. 36, 46–56 (2022).
23. Fuentes, J. J., Fonseca, F., Elices, M., Farré, M. & Torrens, M. erapeutic use of LSD in psychiatry: A systematic review of
randomized-controlled clinical trials. Front. Psychiatry 10, 943 (2020).
24. Johnson, M. W., Richards, W. A. & Griths, R. R. Human hallucinogen research: Guidelines for safety. J. Psychopharmacol. 22,
603–620 (2008).
25. Gujarati, D. N. Basic Econometrics 4th edn. (McGraw Hill, 2003).
26. Montgomery, D. C. Applied Statistics and Probability for Engineers 5th edn. (Wiley, 2010).
27. Carhart-Harris, R. L. & Friston, K. J. REBUS and the anarchic brain: Toward a unied model of the brain action of psychedelics.
Pharmacol. Rev. 71, 316–344 (2019).
28. Olson, D. E. Psychoplastogens: A promising class of plasticity-promoting neurotherapeutics. J. Exp. Neurosci. 12, 1179069518800508
29. Palhano-Fontes, F. et al. e psychedelic state induced by ayahuasca modulates the activity and connectivity of the default mode
network. PLoS ONE 10, e0118143 (2015).
30. B ogenschutz, M. P. & Pommy, J. M. erapeutic mechanisms of classic hallucinogens in the treatment of addictions: from indirect
evidence to testable hypotheses. Drug Test. Anal. 4, 543–555 (2012).
31. Cunningham, K. A. & Anastasio, N. C. Serotonin at the nexus of impulsivity and cue reactivity in cocaine addiction. Neurophar-
macology 76, 460–478 (2014).
32. Howell, L. L. & Cunningham, K. A. Serotonin 5-HT2 receptor interactions with dopamine function: Implications for therapeutics
in cocaine use disorder. Pharmacol. Rev. 67, 176–197 (2015).
33. Sari, Y., Johnson, V. R. & Weedman, J. M. Role of the serotonergic system in alcohol dependence: From animal models to clinics.
Prog. Mol. Biol. Transl. Sci. 98, 401–443 (2011).
34. Bombardi, C. et al. Acute and chronic nicotine exposures dierentially aect central serotonin 2A receptor function: Focus on the
lateral habenula. Int. J. Mol. Sci. 21, 1873 (2020).
35. Higgins, G. A. & Fletcher, P. J. erapeutic potential of 5-HT2C receptor agonists for addictive disorders. ACS Chem. Neurosci. 6,
1071–1088 (2015).
36. Garcia-Romeu, A., Griths, R. R. & Johnson, M. W. Psilocybin-occasioned mystical experiences in the treatment of tobacco
addiction. Curr. Drug. Abuse Rev. 7, 157–164 (2015).
37. Beraldo, L. et al. Spirituality, religiosity and addiction recovery: Current perspectives. Curr. Drug Res. Rev. 11, 26–32 (2019).
38. Galanter, M. Spirituality and addiction: A research and clinical perspective. Am. J. Addict. 15, 286–292 (2006).
39. Grim, B. J. & Grim, M. E. Belief, behavior, and belonging: how faith is indispensable in preventing and recovering from substance
abuse. J. Relig. Health 58, 1713–1750 (2019).
40. McHugh, R. K., Kaufman, J. S., Frost, K. H., Fitzmaurice, G. M. & Weiss, R. D. Positive aect and stress reactivity in alcohol-
dependent outpatients. J. Stud. Alcohol Drugs 74, 152–157 (2013).
41. Wilcox, C. E. & Tonigan, J. S. Changes in depression mediate the eects of AA attendance on alcohol use outcomes. Am. J. Drug.
Alcohol Abuse 44, 103–112 (2018).
42. MacLean, K. A., Johnson, M. W. & Griths, R. R. Mystical experiences occasioned by the Hallucinogen psilocybin lead to increases
in the personality domain of openness. J. Psychopharmacol. 25, 1453–1461 (2011).
43. Weiss, B., Miller, J. D., Carter, N. T. & Keith Campbell, W. Examining changes in personality following shamanic ceremonial use
of ayahuasca. Sci. Rep. 11, 6653 (2021).
44. Zi lberman, N., Yadid, G., Efrati, Y., Neumark, Y. & Rassovsky, Y. Personality proles of substance and behavioral addictions. Addict
Behav 82, 174–181 (2018).
45. Bogenschutz, M. P. et al. Psilocy bin-assisted treatment for alcohol dependence: A proof-of-concept study. J. Psychopharmacol. 29,
289–299 (2015).
Author contributions
G.J. conceptualized the study, conducted the analyses, and contributed to manuscript draing. J.L. contributed
to manuscript draing and editing. Matthew Nock provided supervision, mentorship, and manuscript revisions.
Competing interests
e authors declare no competing interests.
Additional information
Supplementary Information e online version contains supplementary material available at https:// doi. org/
10. 1038/ s41598- 022- 14809-3.
Correspondence and requests for materials should be addressed to G.J.
Content courtesy of Springer Nature, terms of use apply. Rights reserved
Scientic Reports | (2022) 12:10578 |
Reprints and permissions information is available at
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and
institutional aliations.
Open Access is article is licensed under a Creative Commons Attribution 4.0 International
License, which permits use, sharing, adaptation, distribution and reproduction in any medium or
format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the
Creative Commons licence, and indicate if changes were made. e images or other third party material in this
article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the
material. If material is not included in the article’s Creative Commons licence and your intended use is not
permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from
the copyright holder. To view a copy of this licence, visit http:// creat iveco mmons. org/ licen ses/ by/4. 0/.
© e Author(s) 2022
Content courtesy of Springer Nature, terms of use apply. Rights reserved
Terms and Conditions
Springer Nature journal content, brought to you courtesy of Springer Nature Customer Service Center GmbH (“Springer Nature”).
Springer Nature supports a reasonable amount of sharing of research papers by authors, subscribers and authorised users (“Users”), for small-
scale personal, non-commercial use provided that all copyright, trade and service marks and other proprietary notices are maintained. By
accessing, sharing, receiving or otherwise using the Springer Nature journal content you agree to these terms of use (“Terms”). For these
purposes, Springer Nature considers academic use (by researchers and students) to be non-commercial.
These Terms are supplementary and will apply in addition to any applicable website terms and conditions, a relevant site licence or a personal
subscription. These Terms will prevail over any conflict or ambiguity with regards to the relevant terms, a site licence or a personal subscription
(to the extent of the conflict or ambiguity only). For Creative Commons-licensed articles, the terms of the Creative Commons license used will
We collect and use personal data to provide access to the Springer Nature journal content. We may also use these personal data internally within
ResearchGate and Springer Nature and as agreed share it, in an anonymised way, for purposes of tracking, analysis and reporting. We will not
otherwise disclose your personal data outside the ResearchGate or the Springer Nature group of companies unless we have your permission as
detailed in the Privacy Policy.
While Users may use the Springer Nature journal content for small scale, personal non-commercial use, it is important to note that Users may
use such content for the purpose of providing other users with access on a regular or large scale basis or as a means to circumvent access
use such content where to do so would be considered a criminal or statutory offence in any jurisdiction, or gives rise to civil liability, or is
otherwise unlawful;
falsely or misleadingly imply or suggest endorsement, approval , sponsorship, or association unless explicitly agreed to by Springer Nature in
use bots or other automated methods to access the content or redirect messages
override any security feature or exclusionary protocol; or
share the content in order to create substitute for Springer Nature products or services or a systematic database of Springer Nature journal
In line with the restriction against commercial use, Springer Nature does not permit the creation of a product or service that creates revenue,
royalties, rent or income from our content or its inclusion as part of a paid for service or for other commercial gain. Springer Nature journal
content cannot be used for inter-library loans and librarians may not upload Springer Nature journal content on a large scale into their, or any
other, institutional repository.
These terms of use are reviewed regularly and may be amended at any time. Springer Nature is not obligated to publish any information or
content on this website and may remove it or features or functionality at our sole discretion, at any time with or without notice. Springer Nature
may revoke this licence to you at any time and remove access to any copies of the Springer Nature journal content which have been saved.
To the fullest extent permitted by law, Springer Nature makes no warranties, representations or guarantees to Users, either express or implied
with respect to the Springer nature journal content and all parties disclaim and waive any implied warranties or warranties imposed by law,
including merchantability or fitness for any particular purpose.
Please note that these rights do not automatically extend to content, data or other material published by Springer Nature that may be licensed
from third parties.
If you would like to use or distribute our Springer Nature journal content to a wider audience or on a regular basis or in any other manner not
expressly permitted by these Terms, please contact Springer Nature at
ResearchGate has not been able to resolve any citations for this publication.
Full-text available
Cocaine Use Disorder (CUD) is a significant public health problem associated with elevated morbidity and mortality within the United States. Current behavioral treatments have limited efficacy and there are currently no FDA approved pharmacological treatments for CUD. Classic psychedelics might be associated with lowered odds of substance misuse and may effectively treat various forms of addiction. Thus, the goal of this study is to assess protective associations that lifetime use of classic psychedelics may share with CUD within a nationally representative sample of the U.S. We used data from The National Survey on Drug Use and Health (NSDUH) (2015–2019) and conducted survey-weighted multivariable logistic regression to test whether each of four classic psychedelics (peyote, mescaline, psilocybin, LSD) conferred lowered odds of CUD and its related 11 sub-criteria. Participants were 214,505 adults in the NSDUH (2015–2019) aged 18 and older. Peyote conferred lowered odds of CUD, reducing the odds of CUD by over 50% (aOR: 0.47). All other substances (including other classic psychedelics) either shared no association to CUD or conferred increased odds of CUD. Furthermore, sensitivity analyses revealed peyote to confer sharply lowered odds of the majority (seven of 11) of CUD criteria as well (aOR range: 0.26–0.47). Peyote use is associated with lowered odds of CUD. Future inquiries into third variable factors (i.e., demographic/personality profiles of individuals who use peyote, motivational/contextual factors surrounding peyote use) that may underlie our observed associations may reveal protective factors that can inform treatment development for CUD. Additionally, future longitudinal studies can shed further light on whether there is a temporal link between peyote use and lowered odds of CUD.
Full-text available
The present study examines the association between the ceremonial use of ayahuasca—a decoction combining the Banistereopsis caapi vine and N,N-Dimethyltryptamine-containing plants—and changes in personality traits as conceived by the Five-Factor model (FFM). We also examine the degree to which demographic characteristics, baseline personality, and acute post-ayahuasca experiences affect personality change. Participants recruited from three ayahuasca healing and spiritual centers in South and Central America (N = 256) completed self-report measures of personality at three timepoints (Baseline, Post, 3-month Follow-up). Informant-report measures of the FFM were also obtained (N = 110). Linear mixed models were used to examine changes in personality and the moderation of those changes by covariates. The most pronounced change was a reduction in Neuroticism dzself-reportT1–T2 = − 1.00; dzself-reportT1–T3 = − .85; dzinformant-reportT1–T3 = − .62), reflected in self- and informant-report data. Moderation of personality change by baseline personality, acute experiences, and purgative experiences was also observed.
Full-text available
Nicotine addiction is a serious public health problem causing millions of deaths worldwide. Serotonin (5-hydroxytryptamine; 5-HT) is involved in central nervous system (CNS) nicotine effects, and it has been suggested as a promising pharmacological target for smoking cessation. In this regard, what is particularly interesting are the 5-HT2A receptors (5-HT2ARs) and the lateral habenula (LHb), a central area in nicotine addiction that we showed to be under a strong 5-HT2AR-modulation. Single-cell extracellular recording of LHb neurons was used to study the 5-HT2AR function by intravenously administrating the potent agonist TCB-2. Acute nicotine (2 mg/kg, intraperitoneal, i.p.) and chronic nicotine (6 mg/kg/day for 14 days) differently affected both the 5-HT2AR-immuno reactive (IR) neuron number and the 5-HT2AR immunostaining area in the different brain areas studied. After acute nicotine, TCB-2 cumulative doses (5–640 µg/kg, intravenous, i.v.) bidirectionally affected the activity of 74% of LHb recorded neurons. After chronic nicotine treatment, TCB-2 was only capable of decreasing the LHb firing rate. The expression of 5-HT2AR under acute and chronic nicotine exposure was studied in the LHb and in other brain areas involved in nicotine effects in rats by using immunohistochemistry. These data reveal that acute and chronic nicotine differentially affect the 5-HT2AR function in different brain areas and this might be relevant in nicotine addiction and its treatment.
Full-text available
Background Observational data and preliminary studies suggest serotonin 2A agonist psychedelics may hold potential in treating a variety of substance use disorders (SUDs), including opioid use disorder (OUD).AimsThe study aim was to describe and analyze self-reported cases in which naturalistic psychedelic use was followed by cessation or reduction in other substance use.Methods An anonymous online survey of individuals reporting cessation or reduction in cannabis, opioid, or stimulant use following psychedelic use in non-clinical settings.ResultsFour hundred forty-four respondents, mostly in the USA (67%) completed the survey. Participants reported 4.5 years of problematic substance use on average before the psychedelic experience to which they attributed a reduction in drug consumption, with 79% meeting retrospective criteria for severe SUD. Most reported taking a moderate or high dose of LSD (43%) or psilocybin-containing mushrooms (29%), followed by significant reduction in drug consumption. Before the psychedelic experience 96% met SUD criteria, whereas only 27% met SUD criteria afterward. Participants rated their psychedelic experience as highly meaningful and insightful, with 28% endorsing psychedelic-associated changes in life priorities or values as facilitating reduced substance misuse. Greater psychedelic dose, insight, mystical-type effects, and personal meaning of experiences were associated with greater reduction in drug consumption.Conclusions While these cross-sectional and self-report methods cannot determine whether psychedelics caused changes in drug use, results suggest the potential that psychedelics cause reductions in problematic substance use, and support additional clinical research on psychedelic-assisted treatment for SUD.
Full-text available
Lysergic acid diethylamide (LSD) was studied from the 1950s to the 1970s to evaluate behavioral and personality changes, as well as remission of psychiatric symptoms in various disorders. LSD was used in the treatment of anxiety, depression, psychosomatic diseases and addiction. However, most of the studies were not performed under contemporary standards, and it has taken several decades for a resurgence of interest in LSD research and its therapeutic potential for psychiatry. The aim of this review is to identify controlled and randomized clinical trials that assess the potential use of LSD in psychiatry. PRISMA guidelines for systematic review were followed. A literature search of PubMed and Psychedelic bibliography from Multidisciplinary Association for Psychedelic Studies (MAPS) databases was performed as well as a manual search of references from evaluated studies. Only randomized-controlled clinical trials were included. Study quality was systematically calculated by using the Cochrane Collaboration Tool for assessing risk of bias. A final selection of 11 articles was made after considering inclusion and exclusion criteria. LSD was administered to 567 patients in a dose ranging from 20 to 800 mcg. Despite the design heterogeneity of clinical trials, positive results were observed, thus revealing the therapeutic potential of LSD to reduce psychiatric symptomatology, mainly in alcoholism. The vast majority of authors describe significant and positive short-term changes in patients, despite the fact that in some studies an important homogenization was observed between the LSD treatment group and control group at long-term follow-up. Multiple variables regarding LSD treatment therapeutic approach and quality of experience were revealed and related to therapeutic outcomes. LSD is revealed as a potential therapeutic agent in psychiatry; the evidence to date is strongest for the use of LSD in the treatment of alcoholism. Despite the difficulty of designing proper double blind clinical trials with this substance, new studies that conform to modern standards are necessary in order to strengthen our knowledge on its use and open new doors in the future.
Full-text available
Cigarette smoking is the leading cause of preventable disease and death in the United States (1). The prevalence of adult cigarette smoking has declined in recent years to 14.0% in 2017 (2). However, an array of new tobacco products, including e-cigarettes, has entered the U.S. market (3). To assess recent national estimates of tobacco product use among U.S. adults aged ≥18 years, CDC, the Food and Drug Administration (FDA), and the National Cancer Institute analyzed data from the 2018 National Health Interview Survey (NHIS). In 2018, an estimated 49.1 million U.S. adults (19.7%) reported currently using any tobacco product, including cigarettes (13.7%), cigars (3.9%), e-cigarettes (3.2%), smokeless tobacco (2.4%), and pipes* (1.0%). Most tobacco product users (83.8%) reported using combustible products (cigarettes, cigars, or pipes), and 18.8% reported using two or more tobacco products. The prevalence of any current tobacco product use was higher in males; adults aged ≤65 years; non-Hispanic American Indian/Alaska Natives; those with a General Educational Development certificate (GED); those with an annual household income <$35,000; lesbian, gay, or bisexual adults; uninsured adults; those with a disability or limitation; and those with serious psychological distress. The prevalence of e-cigarette and smokeless tobacco use increased during 2017-2018. During 2009-2018, there were significant increases in all three cigarette cessation indicators (quit attempts, recent cessation, and quit ratio). Implementing comprehensive population-based interventions in coordination with regulation of the manufacturing, marketing, and distribution of all tobacco products can reduce tobacco-related disease and death in the United States (1,4).
Full-text available
This study reviews the voluminous empirical evidence on faith’s contribution to preventing people from falling victim to substance abuse and helping them recover from it. We find that 73% of addiction treatment programs in the USA include a spirituality-based element, as embodied in the 12-step programs and fellowships initially popularized by Alcoholics Anonymous, the vast majority of which emphasize reliance on God or a Higher Power to stay sober. We introduce and flesh out a typology of faith-based substance abuse treatment facilities, recovery programs, and support groups. This typology provides important background as we then move on to make an economic valuation of nearly 130,000 congregation-based substance abuse recovery support programs in the USA. We find that these faith-based volunteer support groups contribute up to $316.6 billion in savings to the US economy every year at no cost to tax payers. While negative experiences with religion (e.g., clergy sex abuse and other horrendous examples) have been a contributory factor to substance abuse among some victims, given that more than 84% of scientific studies show that faith is a positive factor in addiction prevention or recovery and a risk in less than 2% of the studies reviewed, we conclude that the value of faith-oriented approaches to substance abuse prevention and recovery is indisputable. And, by extension, we also conclude that the decline in religious affiliation in the USA is not only a concern for religious organizations but constitutes a national health concern.
Full-text available
This paper formulates the action of psychedelics by integrating the free-energy principle and entropic brain hypothesis. We call this formulation relaxed beliefs under psychedelics (REBUS) and the anarchic brain, founded on the principle that-via their entropic effect on spontaneous cortical activity-psychedelics work to relax the precision of high-level priors or beliefs, thereby liberating bottom-up information flow, particularly via intrinsic sources such as the limbic system. We assemble evidence for this model and show how it can explain a broad range of phenomena associated with the psychedelic experience. With regard to their potential therapeutic use, we propose that psychedelics work to relax the precision weighting of pathologically overweighted priors underpinning various expressions of mental illness. We propose that this process entails an increased sensitization of high-level priors to bottom-up signaling (stemming from intrinsic sources), and that this heightened sensitivity enables the potential revision and deweighting of overweighted priors. We end by discussing further implications of the model, such as that psychedelics can bring about the revision of other heavily weighted high-level priors, not directly related to mental health, such as those underlying partisan and/or overly-confident political, religious, and/or philosophical perspectives. SIGNIFICANCE STATEMENT: Psychedelics are capturing interest, with efforts underway to bring psilocybin therapy to marketing authorisation and legal access within a decade, spearheaded by the findings of a series of phase 2 trials. In this climate, a compelling unified model of how psychedelics alter brain function to alter consciousness would have appeal. Towards this end, we have sought to integrate a leading model of global brain function, hierarchical predictive coding, with an often-cited model of the acute action of psychedelics, the entropic brain hypothesis. The resulting synthesis states that psychedelics work to relax high-level priors, sensitising them to liberated bottom-up information flow, which, with the right intention, care provision and context, can help guide and cultivate the revision of entrenched pathological priors.
Background Suicide is one of the leading causes of death worldwide and rates within the United States have risen over the past two decades. Hence, there is a critical need for novel tools to treat suicidal ideation and related mental health conditions. 3,4-Methylenedioxymethamphetamine (MDMA)/ecstasy and classic psychedelics may be two such tools. Aims The aim of this study was to assess non-causal associations between MDMA/ecstasy and classic psychedelic use and psychological distress and suicide risk. Methods In this study, we examined the aforementioned associations among 484,732 adult participants in the National Survey on Drug Use and Health (2008–2019). Results Lifetime MDMA/ecstasy use was associated with reduced odds of past year suicidal thinking (10% reduced odds; odds ratio (OR) = 0.90; 95% confidence interval, CI = (0.84–0.97); p < 0.01) and past year suicidal planning (OR = 0.88; 95% CI = (0.78–0.99); p < 0.05). Furthermore, lifetime psilocybin use was associated with reduced odds of past month psychological distress (OR = 0.78; 95% CI = (0.73–0.84); p < 0.001) and past year suicidal thinking (OR = 0.90; 95% CI = (0.83–0.96); p < 0.01). Finally, lysergic acid diethylamide (LSD) was associated with increased odds of past year suicidal thinking (OR = 1.07; 95% CI = (1.00–1.15); p < 0.05). Conclusion MDMA/ecstasy and psilocybin use are associated with reduced odds of suicidal thinking and related outcomes—though experimental studies are needed to determine whether these associations are causal. These findings call for more research into the efficacy of MDMA/ecstasy and classic psychedelics for treating psychological distress and suicidal thoughts and behaviors, and for updated drug legislation that allows for further investigation into these substances.
Mescaline is a naturally occurring psychoactive alkaloid that has been used as a sacrament by Indigenous populations in spiritual ritual and healing ceremonies for millennia. Despite promising early preliminary research and favorable anecdotal reports, there is limited research investigating mescaline’s psychotherapeutic potential. We administered an anonymous online questionnaire to adults (N = 452) reporting use of mescaline in naturalistic settings about mental health benefits attributed to mescaline. We assessed respondents’ self-reported improvements in depression, anxiety, post-traumatic stress disorder (PTSD), and alcohol and drug use disorders (AUD and DUD). Of the respondents reporting histories of these clinical conditions, most (68–86%) reported subjective improvement following their most memorable mescaline experience. Respondents who reported an improvement in their psychiatric conditions reported significantly higher ratings of acute psychological factors including mystical-type, psychological insight, and ego dissolution effects compared to those who did not report improvements (Cohen’s d range 0.7 – 1.5). Many respondents (35–50%) rated the mescaline experience as the single or top five most spiritually significant or meaningful experience(s) of their lives. Acute experiences of psychological insight during their mescaline experience were associated with increased odds of reporting improvement in depression, anxiety, AUD and DUD. Additional research is needed to corroborate these preliminary findings and to rigorously examine the efficacy of mescaline for psychiatric treatment in controlled, longitudinal clinical trials.